Glenmark Pharmaceuticals Q1 Results FY26: Q1 PAT Falls 86.23% to ₹46.87 Crore; Revenue Up 0.62% YoY

Glenmark Pharmaceuticals  Q1 Results FY26: Glenmark Pharmaceuticals posted its Q1 results on 14th August 2025. The company posted robust numbers, with Q1 PAT standing at ₹46.87 crores against revenue of ₹3,264.44 crores. During Q1 FY26, the profit decrease of the company was recorded at 86.23% YoY, and the revenue increase for the same period was 0.62%. 

Glenmark Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Consolidated Figures)

(Figures in crores)

Glenmark Pharmaceuticals Q1 Results FY26: Extracts of FY25 & FY26 (Standalone Figures)

(Figures in crores)

Glenmark Pharmaceuticals Q1 Results FY26 Highlights (Q1 FY26 vs FY25)

• Glenmark Pharmaceuticals clocked Q1 FY26 consolidated revenue of ₹3,264.44 crores vs ₹3,244.19 crores. 
• On the profit front, Glenmark Pharmaceuticals earned a consolidated PAT of ₹46.87 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹340.27 crore. 
• Consolidated PAT fell for the first quarter of FY26, was 86.23% YoY, and revenue rose 0.62% YoY. 
• Glenmark Pharmaceuticals clocked Q1 FY26 standalone revenue of ₹2,394.93 crores vs ₹2,329.54 crores. 
• On the profit front, Glenmark Pharmaceuticals earned a standalone PAT of ₹330.23 crore in Q1 FY26. During FY25, the company’s PAT stood at ₹453.73 crore.
• As per the standalone figures, the quarterly PAT of Glenmark Pharmaceuticals has decreased by 27.22%, and revenue has increased by 2.81% YoY.

Glenmark Pharmaceuticals Share Price Performance

On the opening bell of 18th August 2025, the shares of Glenmark Pharmaceuticals opened at ₹2,020.40 per share. However, the initial gains are wiped out as of now, and Glenmark Pharmaceuticals shares are trading at ₹2,016.40 per share, lower than their opening price. 

Considering the long-term performance, Glenmark Pharmaceuticals shares have yielded close to 23.61% returns in the past 1 year, and 5-year returns stand at 309.80%. Over the maximum timeframe, the Glenmark Pharmaceuticals share provided 7,981.46% returns to investors. 

What Analysts Expect Post Q1 Results?

As Glenmark Pharmaceuticals has posted robust Q1 results for FY26, analysts are expecting positive trends in its share price. As per the analysts, Glenmark Pharmaceuticals’s share price could reach ₹2,934.00 per share in the coming year, and in downtrends, the share price could hit the level of ₹1,500.00 per share. However, one must ignore the risk of volatility in the stock market and invest in Glenmark Pharmaceuticals shares after thorough research. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.

Recent Articles

Max Healthcare Q1 Results FY26: Q1 PAT Rises 30.35% to ₹307.97 Crore; Revenue Up 31.41% YoY

Minda Corporation Q1 Results FY26: Q1 PAT Rises 1.73% to ₹65.31 Crore; Revenue Up 16.23% YoY

Bharat Dynamics Q1 Results FY26: Q1 PAT Rises 154.30% to ₹18.35 Crore; Revenue Up 29.69% YoY

Elitecon International Q1 Results FY26: Q1 PAT Rises 349.99% to ₹20.41 Crore; Revenue Up 301.98% YoY

Elgi Equipments Q1 Results FY26: Q1 PAT Rises 17.58% to ₹85.60 Crore; Revenue Up 8.19% YoY

Aavas Financier Q1 Results FY26: Q1 PAT Rises 10.41% to ₹139.23 Crore; Revenue Up 15.70% YoY

Regaal Resources IPO GMP: Day 2 IPO Live Updates